NEW YORK –Swedish personalized cancer genomics startup Saga Diagnostics and Rostock, Germany-based SensID said on Wednesday that they have partnered to develop control reagents for cancer mutation detection.
The European collaborators will use SensID's controls with Saga's digital PCR-based Sagasafe technology, which can detect and quantify circulating tumor DNA in cancer patients at ultra-low allelic frequencies (AF).